Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV is demonstrating a commitment to advancing its pipeline of gene therapies, highlighted by strong data from ongoing Phase 1/2 studies of AMT-130 for Huntington's disease, which management asserts possesses an unprecedented efficacy and biomarker profile. Additionally, the company's recent positive reviews from an Independent Data Monitoring Committee (IDMC) signal encouraging progress in clinical trials, such as the GenTLE trial for mesial temporal lobe epilepsy, bolstering confidence in its developmental pathway. Furthermore, management’s assurance regarding the favorable risk-benefit profile of AMT-130, alongside the absence of new concerns from regulatory bodies, supports a positive outlook for uniQure’s future growth potential within the gene therapy sector.

Bears say

uniQure NV faces significant challenges that contribute to a negative outlook on its stock. The company has incurred losses since its inception and lacks a revenue-generating product, which raises financial risks, particularly given its status as a clinical-stage entity. Additionally, recent setbacks regarding AMT-130's regulatory approval process, combined with intensified market competition for similar therapies, may further hinder its ability to penetrate the market and achieve timely commercialization.

uniQure (QURE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 10 analysts, uniQure (QURE) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.